Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05430009 | Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | unknown | Phase 1 | 12 | VA Ann Arbor Healthcare SystemFED | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | unknown | Phase 2 | 190 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04197076 | Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB | unknown | — | 200 | Shanghai Chest HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05477615 | Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | unknown | Phase 2 | 28 | Jin Hyoung KangOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT03971175 | Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC(PROFILER) | unknown | N/A | 540 | University Hospital TuebingenOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05068024 | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer(FWD1509) | unknown | Phase 1 / Phase 2 | 30 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05458726 | Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC | unknown | Phase 2 | 80 | Peking Union Medical CollegeOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05472467 | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer(IMCORT-2) | unknown | Phase 2 | 35 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05460481 | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | unknown | Phase 2 | 29 | Hunan Cancer HospitalOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05460195 | Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation | unknown | Phase 2 | 42 | Shanghai Chest HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05273814 | Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT04459611 | Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）(neoSCORE) | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05451056 | An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib(breakthrough) | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05448781 | Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC | unknown | Phase 2 | 38 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05027100 | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | unknown | N/A | 33 | Haibo ZhangOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05400304 | Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma | unknown | — | 900 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT05435274 | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 380 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05426317 | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression(Onco-PDL1s/B2M) | unknown | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05414630 | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | unknown | Phase 2 | 30 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05411276 | A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2 | unknown | — | 15 | Beijing Chest HospitalOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05394233 | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05395611 | Exhaled Breath Particles in Lung Cancer | unknown | — | 300 | Lund University HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05387044 | SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | unknown | Phase 2 | 28 | Zhejiang Cancer HospitalOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05387109 | Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer(pcwaintrl) | unknown | Phase 4 | 41 | Tang-Du HospitalOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT05085054 | Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 20, 2022 | clinicaltrials |
| NCT05319886 | Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients(AP) | unknown | — | 40 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT05377788 | Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer | unknown | — | 900 | Samsung Medical CenterOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05380271 | Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC | unknown | Phase 2 | 60 | Gang WuOTHER | 0 | May 18, 2022 | clinicaltrials |
| NCT04052412 | Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer | unknown | Phase 1 | 2 | University of TennesseeOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT03606239 | NSCLC Isotoxic Hypofractionated Chemoradiotherapy(IHRC) | unknown | N/A | 30 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03606291 | NSCLC Isotoxic Hypofractionated Radiotherapy(IHR) | unknown | N/A | 30 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05360979 | A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC | unknown | Phase 2 | 42 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04878107 | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy(SABRE) | unknown | Phase 2 | 88 | Wuhan UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT03563482 | Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy. | unknown | N/A | 500 | Istituto Clinico HumanitasOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05351320 | WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC | unknown | Phase 2 | 40 | Jinming YuOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT03997799 | Comparison of Two Techniques of Uniportal VATS Lobectomies for Clinical Stage I Non-Small Cell Lung Cancer | unknown | N/A | 20 | Pulmonary Hospital ZakopaneOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04743752 | Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer | unknown | — | 200 | Peking University First HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346952 | A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | unknown | Phase 3 | 390 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03679936 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer | unknown | — | 120 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04948047 | Breath Combined With CT for Diagnoses of Pulmonary Nodules | unknown | — | 900 | Peking University People's HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05320458 | Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer | unknown | N/A | 11 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2022source: clinicaltrials